← Back

Wire · operational-macro

FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease ...

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fda.gov →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

The FDA has approved Lembaz (adrabetadex) injection, the first drug shown to reduce the risk of death and extend survival in patients with infantile-onset Niemann-Pick disease type C, a rare neurological lysosomal storage disorder. This treatment is suitable for patients weighing at least 7 kg with symptoms before age 6, providing a new therapeutic option where previous treatments did not reduce mortality.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now access the first approved drug that actually prolongs life for infantile Niemann-Pick disease patients. This approval opens a critical market for rare disease therapies with high unmet need and could accelerate similar drug development.

◆ Coverage

1 source · 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalrare-diseasenpcdrug-therapypediatric-treatment